Tripep AB (publ.)—Interim Report—January - June 2006
• The company had no net sales in the period. • Research and development costs for the first half-year 2006 amounted to SEK 6.8 million (4.5 m). • The results of the double-blind trial on alphaHGA indicated no significant reduction of patient HIV levels in serum, which consequently led to a complete write-down of all capitalised expenditure on the alphaHGA project as of 31 March 2006, which affected the results negatively by SEK 35.0 m. • The loss after tax for the first half-year 2006 was SEK -53.7 million (-11.0 m). • Earnings per share for the first half-year 2006 were SEK -2.39 (-0.66).